AVRO VS ATHA Stock Comparison

Performance

AVRO
100/100

AVRO returned 78.43% in the last 12 months. Based on SPY's performance of -12.98%, its performance is above average giving it a score of 100 of 100.

ATHA
10/100

ATHA returned -50.49% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AVRO
88/100

4 analysts offer 12-month price targets for AVRO. Together, they have an average target of 0, the most optimistic target put AVRO at 0 within 12-months and the most pessimistic has AVRO at 0.

ATHA

"Analyst Price Targets" not found for ATHA

Technicals

AVRO
25/100

AVRO receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

ATHA
21/100

ATHA receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

AVRO
10/100

AVRO has missed earnings 13 times in the last 20 quarters.

ATHA
30/100

ATHA has missed earnings 3 times in the last 20 quarters.

Profit

AVRO
10/100

Out of the last 20 quarters, AVRO has had 1 profitable quarters and has increased their profits year over year on 1 of them.

ATHA
10/100

Out of the last 17 quarters, ATHA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

AVRO
25/100

AVRO has had a lower than average amount of volatility over the last 12 months giving it a score of 25 of 100.

ATHA
44/100

ATHA has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Sentiment

AVRO

"Sentiment" not found for AVRO

ATHA
66/100

ATHA had a bullish sentiment score of 66.42% across Twitter and StockTwits over the last 12 months. It had an average of 2.00 posts, 0.00 comments, and 0.12 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

AVROBIO, Inc. Common Stock Summary

Nasdaq / AVRO

Healthcare

Biotechnology

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Athira Pharma, Inc. Common Stock Summary

Nasdaq / ATHA

Healthcare

Biotechnology

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Power up your portfolio